BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol 2021;33:371-7. [PMID: 34230439 DOI: 10.1097/BOR.0000000000000816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J, Zou L, Xu Y, Xu X. Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr 2022;10:962585. [DOI: 10.3389/fped.2022.962585] [Reference Citation Analysis]
2 McLellan K, Papadopoulou C. Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis. Curr Rheumatol Rep 2022. [PMID: 35680774 DOI: 10.1007/s11926-022-01076-4] [Reference Citation Analysis]
3 Hinze C, Dressler F, Schara-schmidt U, Haas J. Juvenile Dermatomyositis. Aktuelle Rheumatologie 2022;47:99-109. [DOI: 10.1055/a-1769-4299] [Reference Citation Analysis]